肝肾综合征的发病机制

廖献花; 叶俊钊; 钟碧慧

doi:10.3969/j.issn.1001-5256.2020.11.002

肝肾综合征的发病机制

DOI: 10.3969/j.issn.1001-5256.2020.11.002

中山大学附属第一医院消化内科

基金项目:

国家自然科学基金（81870404）；

详细信息

中图分类号: R575.2;R692
计量
- 文章访问数: 5173
- HTML全文浏览量: 78
- PDF下载量: 277
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-24
- 出版日期: 2020-11-20

Pathogenesis of hepatorenal syndrome

Department of Gastroenterology,The First Affiliated Hospital of Sun Yat-sen University

Research funding:

摘要

摘要:
肝肾综合征（HRS）是终末期肝病患者常见的严重并发症之一。HRS预后差、病死率高,对其发病机制的深入研究有助于精准预防和治疗。虽然目前HRS的确切发病机制仍未完全阐明,但临床对HRS发病机制的研究步伐一直在前进,不仅对经典的机制——内脏血管扩张假说继续丰富完善,而且对全身性炎症、肠道细菌易位在其发病的作用有了新认识,并对心脏功能障碍参与HRS的机制提出了新的心肾综合征概念,更在肾脏病理方面提出了质疑和挑战。对近年来HRS的发病机制研究进展及其对临床工作的启示作一评述。
- 肝硬化 /
- 肝肾综合征 /
- 急性肾损伤 /
- 心肌疾病
Abstract:
Hepatorenal syndrome( HRS) is one of the common serious complications in patients with end-stage liver disease and has poor prognosis and high mortality,and in-depth studies on its pathogenesis will help to achieve precise prevention and treatment. Although the exact pathogenesis of HRS has not yet been fully elucidated,achievements have been made in the pathogenesis of HRS. The classic mechanism of the hypothesis of visceral vasodilation continues to be enriched and perfected,and new understandings have been gained for the role of systemic inflammation and intestinal bacterial translocation in pathogenesis. In addition,a new concept of cardiorenal syndrome is put forward for the involvement of cardiac dysfunction in HRS,and renal pathology has been questioned and challenged. This article reviews the research advances in the pathogenesis of HRS in recent years and related implications for clinical work.
- liver cirrhosis /
- hepatorenal syndrome /
- acute kidney injury /
- cardiomyopathies

HTML全文

参考文献(34)

[1] GINES A,ESCORSELL A,GINES P,et al. Incidence,predictive factors,and prognosis of the hepatorenal syndrome in cirrhosis with ascites[J]. Gastroenterology,1993,105(1):229-236.

[2] OLIVERA-MARTINEZ M,SAYLES H,VIVEKANANDAN R,et al. Hepatorenal syndrome:Are we missing some prognostic factors?[J]. Dig Dis Sci,2012,57(1):210-214.

[3] AMIN AA,ALABSAWY EI,JALAN R,et al. Epidemiology,pathophysiology,and management of hepatorenal syndrome[J]. Semin Nephrol,2019,39(1):17-30.

[4] RIVOLTA R,MAGGI A,CAZZANIGA M,et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites[J]. Hepatology,1998,28(5):1235-1240.

[5] MINDIKOGLU AL,DOWLING TC,WONG-YOU-CHEONG JJ,et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate,renal plasma flow,renal resistive indices and biomarkers measurements[J]. Am J Nephrol,2014,39(6):543-552.

[6] MINDIKOGLU AL,PAPPAS SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol,2018,16(2):162-177. e1.

[7] LLUCH P,MAURICIO MD,VILA JM,et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome[J]. Exp Biol Med(Maywood),2006,231(1):70-75.

[8] NIJVELDT RJ,TEERLINK T,SIROEN MP,et al. The liver is an important organ in the metabolism ofasymmetrical dimethylarginine(ADMA)[J]. Clin Nutr,2003,22(1):17-22.

[9] NIJVELDT RJ,TEERLINK T,van LEEUWEN PA. The asymmetrical dimethylarginine(ADMA)-multiple organ failure hypothesis[J]. Clin Nutr,2003,22(1):99-104.

[10] MARTIN PY,GINES P,SCHRIER RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis[J]. N Engl J Med,1998,339(8):533-541.

[11] NIJVELDT RJ,TEERLINK T,van der HOVEN B,et al. Asymmetrical dimethylarginine(ADMA)in critically ill patients:High plasma ADMA concentration is an independent risk factor of ICU mortality[J]. Clin Nutr,2003,22(1):23-30.

[12] VALLANCE P,LEONE A,CALVER A,et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure[J]. Lancet,1992,339(8793):572-575.

[13] MINDIKOGLU AL,DOWLING TC,MAGDER LS,et al. Estimation of glomerular filtration rate in patients with cirrhosis by using new and conventional filtration markers and dimethylarginines[J]. Clin Gastroenterol Hepatol,2016,14(4):624-632. e2.

[14] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.

[15] NAZAR A,GUEVARA M,SITGES M,et al. LEFT ventricular function assessed by echocardiography in cirrhosis:Relationship to systemic hemodynamics and renal dysfunction[J]. J Hepatol,2013,58(1):51-57.

[16] KAZORY A,RONCO C. Hepatorenal syndrome or hepatocardiorenal syndrome:Revisiting basic concepts in view of emerging data[J]. Cardiorenal Med,2019,9(1):1-7.

[17] RUIZ-DEL-ARBOL L,MONESCILLO A,AROCENA C,et al. Circulatory function and hepatorenal syndrome in cirrhosis[J]. Hepatology,2005,42(2):439-447.

[18] NADIM MK,KELLUM JA,DAVENPORT A,et al. Hepatorenal syndrome:The 8th international consensus conference of the Acute Dialysis Quality Initiative(ADQI)group[J]. Crit Care,2012,16(1):r23.

[19] THABUT D,MASSARD J,GANGLOFF A,et al. Model for endstage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J]. Hepatology,2007,46(6):1872-1882.

[20] CLARIA J,STAUBER RE,COENRAAD MJ,et al. Systemic inflammationin decompensated cirrhosis:Characterization and role in acuteon-chronic liver failure[J]. Hepatology,2016,64:1249-1264.

[21] JO SK,CHA DR,CHO WY,et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells[J]. Nephron,2002,91(3):406-415.

[22] NAVASA M,FOLLO A,FILELLA X,et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis:Relationship with the development of renal impairment and mortality[J]. Hepatology,1998,27(5):1227-1232.

[23] SHAH N,MOHAMED FE,JOVER-COBOS M,et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis[J]. Liver Int,2013,33(3):398-409.

[24] SHAH N,DHAR D,EL ZAHRAA MOHAMMED F,et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression[J]. J Hepatol,2012,56(5):1047-1053.

[25] FERNANDEZ J,NAVASA M,PLANAS R,et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis[J]. Gastroenterology,2007,133(3):818-824.

[26] WONG F,PAPPAS SC,BOYER TD,et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J].Clin Gastroenterol Hepatol,2017,15(2):266-272. e1.

[27] ACEVEDO J,FERNANDEZ J,PRADO V,et al. Relative adrenal insufficiency in decompensated cirrhosis:Relationship to short-term risk of severe sepsis,hepatorenal syndrome,and death[J]. Hepatology,2013,58(5):1757-1765.

[28] THEOCHARIDOU E,KRAG A,BENDTSEN F,et al. Cardiac dysfunction in cirrhosis-does adrenal function play a role? A hypothesis[J]. Liver Int,2012,32(9):1327-1332.

[29] van SLAMBROUCK CM,SALEM F,MEEHAN SM,et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction[J]. Kidney Int,2013,84(1):192-197.

[30] BARRETO R,FAGUNDES C,GUEVARA M,et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis:Natural history,outcome of kidney function,and survival[J]. Hepatology,2014,59(4):1505-1513.

[31] TRAWALEJM,PARADIS V,RAUTOU PE,et al. The spectrum of renal lesions in patients with cirrhosis:A clinicopathological study[J]. Liver Int,2010,30(5):725-732.

[32] MEHTA G,MOOKERJEE RP,SHARMA V,et al. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure[J]. Liver Int,2015,35(3):724-734.

[33] DAVENPORT A,SHEIKH MF,LAMB E,et al. Acute kidney injury in acute-on-chronic liver failure:Where does hepatorenal syndrome fit?[J]. Kidney Int,2017,92(5):1058-1070.

[34] ANGELI P,GARCIA-TSAO G,NADIM MK,et al. News in pathophysiology,definition and classification of hepatorenal syndrome:A step beyond the International Club of Ascites(ICA)consensus document[J]. J Hepatol,2019,71(4):811-822.

施引文献

资源附件(0)

访问统计